Wockhardt Q1 FY25 revenue up 14%
EBITDA for Q1 FY25 is at Rs. 100 crore compared to Rs. 32 crore in the previous year
EBITDA for Q1 FY25 is at Rs. 100 crore compared to Rs. 32 crore in the previous year
This accelerates the clinical-to-commercial process timeline and enables customers to develop the right molecule
Reported profit after tax declined 19% year-on-year to Rs 76 crores
The integrated company delivers a broad portfolio of over 30,000 lab products across microscopy, histology, and other research areas
The pooled prevalence of GERD in the Indian population is 15.6 %
Protein research is key to advancing our understanding of human biology and delivering on the promise of precision medicine
Dr. Roopal Thakkar joined Abbott/AbbVie in 2003 as part of the Physician Development Program
Zealand Pharma anticipates initiation of a Phase 2b clinical trial in H2 2024
Co-founder and previous CEO Lowry Curley becomes Chief Scientific Officer
Subscribe To Our Newsletter & Stay Updated